This report is designed for companies and decision-makers seeking actionable insights on market size, growth, trends, and competitive strategies to drive expansion and success in the Advanced Liver Cancer industry.
What is the projected value of the advanced liver cancer market by 2029?
The advanced liver cancer market size has grown rapidly in recent years. It will grow from $1.89 billion in 2024 to $2.17 billion in 2025 at a compound annual growth rate (CAGR) of 15.2%. The growth in the historic period can be attributed to increasing awareness towards liver cancer, increasing patient pool, growing demand for targeted therapies, expanding healthcare infrastructure, and growing demand for minimally invasive treatments.
The advanced liver cancer market size is expected to see rapid growth in the next few years. It will grow to $3.78 billion in 2029 at a compound annual growth rate (CAGR) of 14.8%. The growth in the forecast period can be attributed to the growing incidence of liver cancer, incremental healthcare spending, increasing prevalence of genetic conditions, increasing adoption of precision medicine, and increasing adoption of screening and diagnostic tests. Major trends in the forecast period include the integration of artificial intelligence in treatment, the development of innovative drugs and treatment, expanding research and development activities, the development in targeted therapeutics, and growing demand for personalized medicine.
Download Your Free Sample PDF:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20706&type=smp
How are technological advancements fueling growth in the advanced liver cancer market?
The rising prevalence of long-term hepatitis infections is expected to propel the growth of the advanced liver cancer market going forward. Long-term hepatitis infections are long-lasting viral infections that endure for over six months and can result in liver damage, cirrhosis, or liver cancer. The increase in long-term hepatitis infections can be attributed to factors such as inadequate screening and vaccination and delayed access to treatment. Chronic infections with hepatitis B (HBV) or hepatitis C (HCV) are among the leading causes of liver cirrhosis and hepatocellular carcinoma (HCC), the most common form of liver cancer. Long-term viral infections can lead to liver inflammation, liver damage, and eventually cancer over time. As these infections remain prevalent, more individuals are at risk of developing advanced liver cancer. For instance, in April 2024, according to the World Health Organization, a Switzerland-based intergovernmental organization, in 2022, chronic hepatitis B affected 254 million people worldwide, with 1.2 million new cases reported each year. Therefore, the rising prevalence of long-term hepatitis infections is driving the growth of the advanced liver cancer market.
Which segment currently leads the advanced liver cancer market in terms of revenue share?
The advanced liver cancer market covered in this report is segmented –
1) By Test Type: Imaging Test, Biopsy, Genomic Test, Other Test Types
2) By Technology: Fluorescent In Situ Hybridization, Next Generation Sequencing, Fluoroimmunoassay, Comparative Genomic Hybridization, Immunohistochemical, Other Technologies
3) By Distribution Channel: Direct Tenders, Retail Sales, Other Distribution Channel
4) By Application: Screening, Diagnostic And Predictive, Prognostic, Research
5) By End-User: Hospitals, Cancer Research Centers, Academic Institutes, Diagnostic Centers, Ambulatory Surgical Centers, Other End-Users
Subsegments:
1) By Imaging Test: Ultrasound, CT (Computed Tomography) Scan, MRI (Magnetic Resonance Imaging), PET (Positron Emission Tomography) Scan
2) By Biopsy: Needle Biopsy, Laparoscopic Biopsy, Surgical Biopsy
3) By Genomic Test: Next-Generation Sequencing (NGS), PCR (Polymerase Chain Reaction) Testing, Genetic Mutation Profiling
4) By Other Test Types: Serum Biomarker Testing, Liver Function Tests, Alpha-Fetoprotein (AFP) Test, Elastography Tests
View The Full Market Report:
https://www.thebusinessresearchcompany.com/report/advanced-liver-cancer–global-market-report
What technological trends are expected to redefine the advanced liver cancer market?
Major companies operating in the advanced liver cancer market are focusing on developing innovative drugs, such as human monoclonal antibodies, to improve treatment efficacy and minimize side effects for better patient outcomes. A human monoclonal antibody is a lab-created molecule that imitates the immune system’s function in combating harmful pathogens or cancer cells. It targets specific antigens on the surface of these harmful entities to trigger an immune response. For instance, in October 2022, AstraZeneca, a US-based pharmaceutical company, announced that the US Food and Drug Administration (FDA) approved Imjudo (tremelimumab) in combination with Imfinzi (durvalumab) for the treatment of adult patients with unresectable hepatocellular carcinoma (HCC), the most common form of liver cancer. This approval was based on results from the HIMALAYA Phase III trial, which demonstrated that this combination therapy reduced the risk of death by 22% compared to sorafenib, with approximately 31% of patients alive after three years versus 20% for those on sorafenib. The regimen, known as STRIDE, involves a single dose of Imjudo followed by regular doses of Imfinzi every four weeks, offering a new therapeutic option for patients facing limited treatment choices.
Who are the top competitors in the global advanced liver cancer market?
Major companies operating in the advanced liver cancer market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, Eli Lilly and Company, Stryker Corporation, Agilent Technologies Inc., Eisai Co. Ltd., Jiangsu Hengrui Pharmaceutical Co. Ltd, Exelixis Inc., Sirtex Medical Limited, Eureka Therapeutics, Abbisko Therapeutics Co. Ltd., Binhui Biopharmaceutical Co. Ltd., Tempest Therapeutics Inc., Auransa Inc., Mina Alpha Limited, Jennerex Inc.
What regional dynamics are shaping the future of the global advanced liver cancer market?
North America was the largest region in the advanced liver cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the advanced liver cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Can Companies Use The Advanced Liver Cancer Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.
Purchase The Report And Get A Swift Delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20706
Need Customized Data On Advanced Liver Cancer Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you’re entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
Request Customized Data:
https://www.thebusinessresearchcompany.com/customise?id=20706&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
